San Francisco, United States
Vial, founded in 2020, is carving a niche in the biotechnology and pharmaceutical industries with its commitment to developing next-generation biologics and RNA therapeutics.
Headquartered in the United States, this innovative pharma company is targeting numerous areas of unmet medical need, setting it apart from its peers. Its vision and proactive approach underscore its potential to deliver best-in-class medical solutions.
The company's growth trajectory caught the attention of investors, leading to a substantial $67.00M Series B funding round completed on 01 December 2022. Notable investors in this round include BoxGroup, General Catalyst, Byers Capital, and a host of other influential names such as Josh Buckley and Elena Viboch.
The strong backing from a diverse group of investors not only validates Vial's strategic roadmap but also positions it well to advance its ambitious research and expand its influence in the global biotech sector.
